News

All Press Releases

Stay updated with the latest news and developments from Topas Therapeutics, including corporate announcements, clinical trial progress, and scientific advancements in immunotherapy research.

28 June 2026│ Presentations and Keynotes

Topas Therapeutics with two presentations at the Sixth Newcastle Therapeutic Tolerance Workshop

5 May 2026 │ Scientific Publication

Antigen-specific tolerance and control of autoimmunity effected by liver sinusoidal endothelial cells is unimpaired in liver fibrosis

14 April 2026 │ Presentations and Keynotes

Topas presents nanoparticle platform at Nanotech in Life Science conference

12 March 2026 │ Scientific Publication

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading

4 March 2026 │ Presentations and Keynotes

Topas to present at the 9th Antigen-Specific Immune Tolerance Summit

29 January 2026 │ Scientific Poster

Antigen-specific immune modulation with liver-targeting nanoparticles fosters immune protective regulatory T cells to delay Type 1 Diabetes

6 October 2025 │ Presentations and Keynotes

Topas presents new TPM502 Phase 2a data at UEG Week

18 September 2025 │ Presentations and Keynotes

Topas to present at BioCentury’s GrandRounds Europe

21 August 2025 │ Scientific Poster

Nanoparticles targeting liver sinusoidal endothelial cells improve AAV gene transfer and promote tolerance-spreading to capsid and transgene epitopes

7 August 2025 │ Scientific Publication

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus

6 May 2025 │ Press Release

Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients

5 May 2025 │ Topas in the News

Endpoints News – Exclusive: Topas claims success in early test of ‘immune tolerance’ therapy for celiac disease.

24 April 2025 │ Press Release

Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego

17 March 2025 │ Press Release

Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology

22 November 2024 │ Topas in the News

Going Public -“We still believe we’re an undiscovered gem” Charting the Future of Immune Tolerance: Insights from the CEO of TOPAS

Connect with our team and learn how we are transforming the treatment of autoimmune diseases